AI could play a key role in improving the effects of prostate cancer treatment

A study led by UCLA researchers shows that artificial intelligence (AI) could play a key role in improving the results of treatment for men with prostate cancer, helping doctors determine who is more likely to benefit from a partial gland.

The researchers found that an AI tool called Reblown AI, developed by UCLA and Avenda Health researchers, accurately assesses the volume of prostate volume and helps detect patients with greater chance of successful treatment.

The study, published in the Bjui Compass, suggests that the use of AI to measure tumor size could reduce treatment failures by more than 70%.

Using AI to more accurately measure the size of a person’s prostate volume, we can better predict who is likely to be cured with focal remedies such as partial gland.

Dr. Wayne Brisbane, Assistant Professor of Urology at David Geffen School of Medicine in Ucla, a member of UCLA Health Jonsson Comprehensive Cancer Center and first author of the study

Partial cryology freezes and destroys only the cancer part of the prostate, instead of removing or healing the entire gland. The approach eliminates cancer cells, while minimizing damage to vital areas, resulting in fewer side effects than surgery or radiation and offering patients a better quality of life. The technique involves the use of imaging guidance, such as magnetic resonance imaging, to accurately detect the tumor and guide the treatment. Real -time portrayal during the process helps to monitor the progress of treatment and ensures the exact delivery of energy in the area intended.

Current methods, however, tend to underestimate how large the tumor is and can lose smaller cancers, which can lead to incomplete treatment and recurrence of cancer.

Refold AI helps with this issue by analyzing MRI scanning data and biopsies to create a detailed, three -dimensional prostate volume map. This helps doctors more accurately see the actual size and boundaries of cancer.

To evaluate the accuracy of the AI ​​software, the team participated in 204 men with localized prostate cancer undergoing some Cryoablation gland in a clinical trial in UCLA between 2017 and 2022.

In the test, doctors used AI to create a 3D map of each tumor, appreciating its true volume. The volume volume with traditional indicators such as tumor levels and PSA levels to predict the effects of treatment were compared.

They found that the tumor tumor was the strongest predictor of the success of the treatment, while the degree of tumor was not associated with a successful result. Patients with tumors of less than 1.5 cubic centimeters had significantly better results after cryotherapy and these men were less likely to need further treatment or develop metastases. Using this tumor tumor limit as an eligibility criterion would prevent 72% of treatment failures, according to the study.

“With AI launch, doctors now have a method to determine the volume of cancer within a prostate tumor,” said Dr. Leonard Marks, Professor and Dekernion resulted in a chair in Urology at David Geffen School of Medicine in Ucla, Cancer Center and superior author of the study. “Such a method was not previously available. It is important because tumor volume is an important decisive factor in success or failure of treatment.

While these findings are very promising, researchers emphasize the need for larger multi -centers tests to confirm their results.

“The study marks a significant progress in the integration of AI into decision -making for the treatment of prostate cancer, offering the opportunity for more personalized prostate cancer care,” Brisbane said.

Collaborative research in UCLA and Avenda health care supported by UCLA, which led to the development of Reflord AI was supported by grants by National Institutes of Health.

Other writers include Alan Priester, Anissa Nguyen, Mark Topoozian, Merdie Delfin, Samantha Gonzalez, Kyla Grunden, Shannon Richardson and Shyan Natarajan from Ucla and Sakina Mota by Avenda Health.

Marks and Natarajan are co -founders of Avenda Health.